Cell Bank Sizing Calculator

Plan your MCB and WCB vial requirements, QC allocation, stability testing schedule, and product lifecycle cell banking needs. Compliant with ICH Q5D guidance.

Cell Type Preset
Cells per Vial (x106)
Fill Volume (mL)
Cryoprotectant
Banking Date
MCB Vial Calculator ?
Total WCBs Over Lifecycle
Vials per WCB Derivation
QC Vials ?
Stability Vials
Regulatory Retention Vials
Safety Margin (%)
WCB Vial Calculator ?
Batches per WCB Campaign
Vials per Batch Inoculation
QC Vials
Stability Vials
Retention Vials
Safety Margin (%)
QC Allocation Planner ?
Stability Schedule Generator ?
Vials per Timepoint
Schedule
Custom Timepoints (months, comma-sep)
Lifecycle Planner

Estimate total WCB and MCB vial requirements across the entire product development lifecycle.

Phase I Batches
Phase II Batches
Phase III Batches
Commercial Batches/Year
Years of Commercial Production
Batches per WCB Campaign
Vial Fill Optimization
Total Cells Harvested (x106)
Target Cells/Vial (x106)
Fill Volume per Vial (mL)
Cryopreservation Protocol Reference

Standard freeze and thaw protocols for mammalian cell banking. Adapt timings and volumes to your specific cell line and SOP.

Freeze Protocol
1
Harvest cells in log phase (>90% viability). Centrifuge 200-300 x g, 5 min.
2
Count cells and assess viability. Record pre-freeze VCD and viability.
3
Resuspend in cold cryo medium at target density. Add DMSO dropwise while mixing gently.
4
Aliquot into pre-labeled cryovials. Work quickly — DMSO is cytotoxic at room temperature.
5
Controlled-rate freeze at -1C/min (Mr. Frosty or CRF). Hold at -80C overnight.
6
Transfer to LN2 storage (vapor phase recommended). Log location in inventory system.
Thaw Protocol
1
Pre-warm media to 37C. Prepare vessel with appropriate volume of complete growth medium.
2
Rapid thaw in 37C water bath. Swirl gently until only a small ice crystal remains (~2 min).
3
Dilute slowly — add warm media dropwise (1:10 ratio) to reduce osmotic shock from DMSO.
4
Centrifuge at 200 x g for 5 min to pellet cells and remove DMSO-containing supernatant.
5
Resuspend in fresh warm media. Seed into vessel at recommended density for cell type.
6
Assess at 24h — count cells and viability. Post-thaw viability should be >70% (ideally >85%).
Post-Thaw Viability Benchmarks
CHO-K1/DG44: >85%
HEK293/293T: >80%
Vero: >80%
Hybridoma: >75%
Jurkat/T cells: >70%
Primary cells: >60%
iPSC/ESC: >50% (variable)
E. coli: >90% (glycerol stock)
Common Cryopreservation Media
Standard (CHO/HEK): 90% complete media + 10% DMSO
With serum: 70% media + 20% FBS + 10% DMSO
Low DMSO: 95% media + 5% DMSO + 5% glycerol
CryoStor CS10: Serum-free, chemically defined (GMP-grade)
E. coli glycerol: LB + 15-25% glycerol (no DMSO)
Yeast: YPD + 15% glycerol

How to plan cell bank sizing for biopharmaceutical production

Cell bank sizing is a critical early step in biopharmaceutical development. The Master Cell Bank (MCB) and Working Cell Bank (WCB) form the foundation of your manufacturing supply chain. Proper planning ensures you have sufficient vials for production campaigns, QC testing, stability studies, and regulatory retention throughout the entire product lifecycle.

ICH Q5D provides guidance on the derivation and characterization of cell substrates used for production of biotechnological/biological products. The two-tiered cell banking system (MCB/WCB) protects your limited MCB supply while providing adequate WCB material for routine manufacturing. Key considerations include: total production batches across all clinical and commercial phases, vials consumed per WCB derivation and production inoculation, QC testing panel requirements, and stability testing schedules.

A well-planned cell banking strategy includes safety margins of 10-20% to account for unexpected needs, failed batches, and re-testing. Regulatory retention vials must be maintained for the lifetime of the product plus a defined period after market withdrawal.

Related Articles

Cell Bank Management
MCB/WCB best practices and ICH Q5D compliance

Frequently Asked Questions

What is the difference between a Master Cell Bank and a Working Cell Bank?

A Master Cell Bank (MCB) is the primary cryopreserved stock derived from the original cell clone, manufactured under GMP conditions and fully characterized. A Working Cell Bank (WCB) is derived from one or more vials of the MCB by expansion and cryopreservation. WCBs are used for routine production campaigns, protecting the limited MCB supply.

How many vials should a Master Cell Bank contain?

An MCB typically contains 200-500 vials, enough to derive all WCBs needed over the entire product lifecycle (clinical through commercial), plus vials for QC testing, stability studies, regulatory retention, and a safety margin of 10-20%.

What QC tests are required for cell banks per ICH Q5D?

ICH Q5D requires identity testing, sterility, mycoplasma testing, adventitious virus testing (in vitro and in vivo), species-specific virus testing (e.g., retrovirus for CHO), karyology, and viability post-thaw. Additional tests may include electron microscopy and PCR panels.

What is the recommended stability testing schedule for cell banks?

Stability testing should be performed at defined intervals: typically 0, 3, 6, 12, 24, and 36 months, with extended testing every 1-2 years thereafter. Two vials per timepoint is standard for viability assessment, sterility, and cell characterization.

How do I calculate the number of WCBs needed for a product lifecycle?

Sum the total production batches across all clinical phases and commercial manufacturing, then divide by the number of batches per WCB campaign. Add a safety margin of 10-20% for failed batches and re-derivations.

What is the typical cell concentration for cryopreservation vials?

For CHO cells, the standard is 1x10^7 cells per vial in 1 mL with 10% DMSO. HEK293 and hybridoma cells are typically frozen at 5x10^6 cells/vial. E. coli glycerol stocks are prepared at OD600=1 in 1 mL with 15-25% glycerol.